First Tracks Biotherapeutics (NASDAQ:TRAX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) have been given an average recommendation of “Moderate Buy” by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $40.00.

TRAX has been the topic of several recent research reports. Wells Fargo & Company initiated coverage on shares of First Tracks Biotherapeutics in a research report on Monday, June 8th. They issued an “overweight” rating and a $30.00 price objective on the stock. UBS Group started coverage on First Tracks Biotherapeutics in a research report on Tuesday, April 21st. They issued a “buy” rating and a $45.00 target price for the company. Piper Sandler started coverage on First Tracks Biotherapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $54.00 price target on the stock. Barclays began coverage on First Tracks Biotherapeutics in a report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price target on the stock. Finally, HC Wainwright boosted their price objective on shares of First Tracks Biotherapeutics from $30.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday.

First Tracks Biotherapeutics Price Performance

Shares of NASDAQ:TRAX traded up $3.84 on Friday, hitting $36.24. 1,919,842 shares of the company’s stock were exchanged, compared to its average volume of 594,693. First Tracks Biotherapeutics has a 1-year low of $14.72 and a 1-year high of $38.49. The stock has a market capitalization of $1.26 billion and a P/E ratio of -19.70. The stock’s 50-day moving average is $18.46.